Press releases

The Phase II clinical trial aims to evaluate the efficacy, safety and pharmacokinetics of DNV3837 in patients with Clostridioides difficile...

DEINOVE launches the production of a new batch of Phyt-N-Resist® to meet the needs of its distributors and future customers. Several...

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-...

The Deinodrop technology will be co-developed by ESPCI and DEINOVE to accelerate the discovery and identification of bacteria producing new...

Emmanuel PETIOT will resign as Chief Executive Officer ("CEO") as of December 31, 2019 Dr. Charles WOLER, Chairman of the Board of...

This new carotenoid has the particularity of absorbing blue light, which is responsible for premature skin ageing, the appearance of skin...

DEINOVE will present DNV3837/DNV3681, its antibiotic candidate targeting both urgent threats to public health and bioterrorism pathogens...

Launch of the Phase II trial testing DNV3837 for first-line treatment of moderate to severe Clostridioides difficile infections...

DEINOVE strengthens its expertise in the genetic engineering of rare and varied microorganisms to accelerate the discovery and optimization...

New in vitro and clinical efficacy data have been published; Sphingomonas hydrophobicum extract, the active substance of Hebelys®,...